Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know

Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know

Monday, February 13, 2023
Webinar -- 11:30 AM CT
https://cmmglobal1.webex.com/cmmglobal1/onstage/g.php?MTID=ec9df04c4396476f9cbcfdc9b95cf7657 password: 6610

Agenda

  • Introduction
  • Overview of Thyroid Cancer: Most Common Genetic Drivers
  • Biomarker Testing in Thyroid Cancer
  • Clinical Data and Current Indications of Therapies Targeting Common Genetic Drivers in Advanced Thyroid Cancer
  • Audience Question and Answer Session

Faculty

Faculty
Lori J. Wirth, MD

Associate Professor
Medical Oncology
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with thyroid cancers.

Target Audience
This program is intended for endocrinologists and other healthcare professionals who care for patients with thyroid cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive thyroid cancer and RET inhibition in RET-altered thyroid cancer
  • Manage treatment-related symptoms associated with the treatment of RET-altered or NTRK fusion–positive cancer
  • Refer eligible patients with NTRK fusion–positive and RET-altered thyroid cancer for ongoing clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.